Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fennec Pharmaceuticals reports Q1 loss, sees growth in new therapies

Fennec Pharmaceuticals' Q1 2023 earnings call highlighted a mix of financial results, market strategies, and analyst inquiries. Despite challenges in achieving profitability, the company showcased strengths in product launches and market acceptance. Opportunities for growth through expanded adoption, market strategies, and R&D investments were discussed.

Fennec Pharmaceuticals reports robust revenue growth and strategic milestones in Q2 2023

Fennec Pharmaceuticals demonstrated strong revenue growth and key regulatory milestones in Q2 2023, positioning the company for future success.
While facing financial challenges and operational inquiries, Fennec's strategic focus on commercial expansion and patient support programs remains a key strength.
With a solid cash position and experienced leadership, Fennec is well-positioned to capitalize on market opportunities and drive further growth in the oncology sector.

Fennec Pharmaceuticals excels in Q3 with PEDMARK growth strategies

Fennec Pharmaceuticals demonstrated robust financial performance and strategic market positioning in Q3 2023, leveraging the successful launch of PEDMARK in the U.S. and plans for European expansion.
While facing challenges in metrics tracking, manufacturing transitions, and pipeline prioritization, the company remains focused on maximizing PEDMARK's market potential and competitive edge.
Opportunities lie in expanding market presence in Europe, negotiating favorable pricing strategies, and solidifying PEDMARK's position as a key therapy alongside cisplatin.

Fennec Pharmaceuticals excels in Q4 2023, secures strategic partnerships

Fennec Pharmaceuticals delivered strong financial results and strategic advancements in Q4 2023, positioning the company for growth.
While facing challenges in increased expenses and access barriers, Fennec's focus on pediatric oncology and strategic partnerships offer promising opportunities.
With a solid financial foundation and market endorsements, Fennec is well-positioned to capitalize on its growth potential and expand its market presence.

Fennec Pharmaceuticals reports solid Q1 performance amidst market challenges

Fennec Pharmaceuticals navigated challenges in Q1 2024 while maintaining strong financial performance and strategic advancements. The company's focus on resolving issues, expanding market reach, and optimizing sales strategies positions it for future success.

Fennec Pharmaceuticals reports solid Q2 performance, eyes market expansion

Fennec Pharmaceuticals' Q2 2024 performance reflects progress in PEDMARK's commercialization and market access.
While facing challenges in specific business segments, the company's strong financial position and strategic partnerships are notable strengths.
Opportunities lie in targeted market expansion and clear communication of growth strategies to investors.

Fennec Pharmaceuticals reports robust Q3 performance and eyes international expansion

Fennec Pharmaceuticals showcased solid financial performance in Q3 2024, with a strong focus on the AYA market.
The company's strategic imperatives for PEDMARK and leadership enhancements position it for future growth.
While challenges exist in increasing awareness and managing expenses, opportunities in revenue growth and market expansion are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fennec Pharmaceuticals received FDA approval for Pedmark, a drug addressing cisplatin-induced ototoxicity in pediatric patients. The National Comprehensive Cancer Network (NCCN) and the European Medicines Agency (EMA) have endorsed Pedmark, strengthening its market prospects.

Fennec Pharmaceuticals Gains Momentum With Industry Endorsements

~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates

~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ® in September 2022 ~

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Adherex Technologies (FENC)

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,  Non-metastatic Solid Tumors ~

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark.​ Additionally, the company secured non-dilutive capital to help initial commercialization efforts. While the market for Pedmark is limited, its critical use in the prevention of cisplatin-related hearing loss in pediatric patients assures market viability.

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale

~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

After two CRLs, PEDMARK has finally been approved for preventing chemo-induced hearing loss in pediatric cancer patients. In addition to being both safe and effective, PEDMARK has not shown itself to interfere with the cancer-fighting properties of chemotherapy agents.

Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

PDUFA for Pedmark (sodium thiosulfate) in treating platinum chemotherapy-induced cytotoxicity (ear toxicity) in children is scheduled on September 23. The company resolved the issues raised in the second CRL within 3 months and announced the NDA acceptance in April this year.

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

100% technical buy signals. 16 new highs and up 22.29% in the last month.

Fennec Pharmaceuticals - Biopharma

Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.

Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ ~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fennec securities between May 28, 2021, and November 26, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's si

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

News for Fennec Pharmaceuticals Stock (FENC)